Sep 17, 2024
Tilburg, 17 September 2024 – Treeway is pleased to announce the successful completion of patient enrollment for the Phase 2A ASURE study. The study is the first randomized, double-blind, placebo-controlled trial aiming to evaluate the safety,...
Jan 18, 2024
In reference to the official press release of our pharma partner Ferrer, we regret to share that the top-line results of the phase 3 clinical study ADORE* show that the primary or key secondary endpoints were not met. In the ADORE study, our lead product TW001 (FAB122...
Mar 6, 2023
Tilburg, March 6, 2023 – Treeway, in collaboration with the Alzheimer Drug Discovery Foundation (ADDF), announces today the successful enrollment of the first patient in the Alzheimer’s Disease Study Using Oral Edaravone (ASURE), Phase 2a clinical trial. The trial...
